All Journals from T Doctorian
Certain antidiabetic therapies have adverse cardiovascular (CV) consequences. The recommendations for CV safety studies for new antidiabetic therapies led to the discovery that the sodium-glucose cotransporter-2 inhibitors (SGLT2is) have benefits in heart failure (HF) management. Mounting evidence from large, international, randomized, placebo-controlled trials have consistently demonstrated a reduction in hospitalizations for heart failure (HHF) among […]